Hou Dayong, a postdoctoral fellow at the University of Hong Kong, has long been engaged in research on the application of in vivo self-assembling peptide nanotechnology in the diagnosis and treatment of urological tumors. In the past five years, he has published over 50 high-level SCI papers, with an H-index of 26. Among them, he has published more than 20 SCI papers as the first author or corresponding author, including Chemical Society Reviews (IF=40.4), Nature Communications (IF=14.7), Science Advances (IF=11.7), JACS (IF=14.4), Angew (IF=16.1), Advanced Materials (IF=27.4), Science Bulletin (IF=18.8), and National Science Review (IF=16.3) in authoritative domestic and international journals.